



BIODIEM LTD  
ABN 20 096 845 993  
Level 4,  
100 Albert Road,  
South Melbourne, Victoria, 3205  
Australia  
Phone: +613 9692 7240  
Web: [www.biodiem.com](http://www.biodiem.com)

## Announcement

### BioDiem Board Changes

**Melbourne, 29 March 2022:** Australian vaccine technology company BioDiem Ltd (“BioDiem”) announced today the appointment of Mr Damien Hannes as chairman of the board, replacing Mr Hugh Morgan AC, effective today. Hugh will remain on the board as a non-executive director.

Mr. Hannes joined the board earlier this year as an independent non-executive director. He has over 25 years of finance, operations, sales and management experience including over 15 years in senior executive capacities. From 2009 to 2019 Mr Hannes was a non-executive director of Sundance Energy Australia Ltd (ASX) and Sundance Energy Inc (NASDAQ) after a re-domicile to the US. Damien has held various other directorships as Chairman and as a non executive Director. He has successfully raised capital and developed and managed mining, commodities trading and manufacturing businesses in the global market.

Mr Hugh Morgan AC has been chairman of BioDiem since 2005 and is a major shareholder of the company. He flagged his intention to retire from the chair role at BioDiem’s 2021 AGM.

BioDiem’s CEO, Julie Phillips said, “The Board warmly welcomes Damien to the role of chairman at an exciting time for the company with our LAIV influenza vaccine’s commercial progress in both China and India. We are most grateful to Hugh for his leadership over a decade and a half, steering the company through its commercial journey. His continuing contribution reflects his commitment to the company’s success”.

- ENDS -

### About BioDiem Ltd

BioDiem is an Australian biopharmaceutical company that is focused on developing and commercialising vaccines and infectious disease therapies. BioDiem’s business model is to generate income from partnerships including with other vaccine and infectious disease treatment companies through existing and new licences to its LAIV vaccine and other technologies. Income comes from licence fees and royalties on sales.

BioDiem’s lead technology is the LAIV (Live Attenuated Influenza Virus) vaccine technology used for production of seasonal and pandemic influenza vaccines and is given intranasally. This technology is licensed currently to two commercial partners, in India and China, and is licenced to the World Health Organisation as part of the Global Pandemic Influenza Action Plan to Increase Vaccine Supply.

Biodiem has two commercial licencees:

- Changchun BCHT Biotechnology Co (China) launched Defluvac™ in China in August 2020; and
- Serum Institute of India’s Nasovac-S™ is marketed in India.

### Further information

Julie Phillips, Chief Executive Officer  
BioDiem Ltd  
Phone +61 3 9692 7240  
Email [jphillips@biodiem.com](mailto:jphillips@biodiem.com)  
Twitter @biodiem @opalbiosciences